Thomas Südhof, MD, is the Avram Goldstein Professor in Stanford University School of Medicine, and serves as a professor of Molecular & Cellular Physiology and Neurosurgery, and, by courtesy, of Psychiatry and Neurology. In addition, he is an investigator of the Howard Hughes Medical Institute, and has been an advisor at Catalio Venture Partners since 2019. Previously Dr Südhof spent 25 years at the University of Texas, Southwestern, where he acted as Chairman of the Department of Neuroscience. Most of his research at that time focused on the mechanisms of synaptic information transmission which have pharmacological consequences for the treatment of neurodegenerative and neuropsychiatric diseases. He is co-founder and member of numerous scientific committees of companies and biotechs based in the United States. Dr Südhof won the Nobel Prize in Physiology or Medicine (shared with James Rothman and Randy Shekman) in 2013, the Albert Lasker Medical Basic Research Award (shared with Richard Scheller), as well as the Bernhard Katz Award of the Biophysical Society (shared with Reinhard Jahn).He holds a Medical Degree from the University of Göttingen Medical School (Germany) and a Doctoral Degree from the Max Planck Institut/University of Göttingen (Germany).
Mr. Remmel is currently a partner of the law firm Pryor Cashman LLP, located in New York City, where he chairs the Banking and Finance practice group. His practice includes corporate and banking financings, issues relating to the Investment Company Act of 1940, and intellectual property and licensing issues, in particular in the biotechnology and bio-cosmeceutical areas. Mr. Remmel serves as a director of Atossa Therapeutics, Inc. (NASDAQ: ATOS), a company focused on developing novel, proprietary therapeutics and delivery methods for the treatment of breast cancer and other breast conditions, of Aufbau Holdings Ltd., an Irish biotechnology company focused on ophthalmology and oncology, and of Cognoptix, Inc., a company focused on the early diagnosis of Alzheimers. He received his J.D. from the Washington & Lee University School of Law in 1979 and his B.A. from Princeton University in 1975. He currently is a doctoral candidate in the Graduate School of Life Sciences of the University of Utrecht, in the Department of Clinical and Translational Oncology, with a thesis project in hyperplasia and early stage breast cancer. He is seconded to the laboratory of David Lyden, M.D., Ph.D., Weill Cornell Medicine, Gale and Ira Drukier Institute for Children's Health.
Mr. Huang is currently Chief Technical Operations Officer and Executive Vice President at Ultragenyx. Mr. Huang joined Ultragenyx in May 2015 and is responsible for leading the technical and pharmaceutical development, manufacturing and supply chain functions covering broad technical modalities like small molecules, recombinant proteins, nucleic acid medicines and AAV gene therapy. This includes product approvals and launches for Mepsevii ®, Crysvita® and Dojolvi®. In addition, Mr. Huang is executive team member responsible for the Gene Therapy Operations and Strategy. Prior to joining Ultragenyx, Mr. Huang was Senior Vice President of Manufacturing and Supply Chain for InterMune Inc., where he led the global manufacturing and supply chain organization for the company which led to the US approval of Esbriet ®. Prior to InterMune, he served as Vice President of Biologics Manufacturing and Development for Allergan, Inc. where he held dual responsibilities in R&D and Global Technical Operations. Earlier in his career, Mr. Huang held positions at Novartis AG (formerly Chiron, Inc), Genentech, Inc., and Synergen (currently Amgen), where he worked in various roles including manufacturing, quality and process and analytical development. Mr. Huang serves on the Board of Directors of CytoDel and Ornovi; and the Technical Advisory Board of Solid Biosciences. Mr. Huang earned a B.A. in chemistry from Knox College.
Mr. Gudger is the Founder and CEO of Eccalon with over twenty years of experience leading middle-market technology companies and senior positions within the Federal government. From 2011-2017, he served as President Barack Obama's Deputy Assistant Secretary of Defense for Manufacturing and Industrial Base Policy (MIBP) and the Director of the Office of Small Business Programs. As the Deputy Assistant Secretary of Defense, Mr. Gudger provided detailed analyses of the increasingly global and financially complex industrial supply chain and took appropriate actions to maintain the health, integrity and technical superiority of the industrial base. In his many roles, Mr. Gudger was also the Defense Department's lead for President Obama's National Network of Manufacturing Innovation, through which he led the establishment of eight manufacturing institutes that focus on additive manufacturing, lightweight metals technology, robotics, and biotechnology. He is credited with reshaping MIBP by creating programs that focus on Business Intelligence, Analytics, and Global Markets to modernize the office's programs and realign its focus areas for the 21st Century. Previously, he served as the Director of the Office of Small Business Programs, where he acted as the principal advisor to the Secretary of Defense on all matters related to small business, and oversaw more than $120 billion of annual awards to small companies. In his past, Mr. Gudger has worked on key technical and financial initiatives with the Federal Deposit Insurance Corporation, Union Bank of Switzerland, AT&T, and founded Solvern Innovations, a cybersecurity solutions company, where he served as its Chairman and Chief Executive Officer. Mr. Gudger received his Bachelor of Sciences degree from the University of Maryland at Baltimore County and his M.B.A. from the University of North Carolina at Chapel Hill.
Ms. Fischbein is currently Managing Director, Healthcare, for Cassel Salpeter & Co., a private investment banking firm. Previously, Ms. Fischbein was Head of Healthcare Investment Banking for Seaport Global and for FBR & Co. and Head of East Coast Biotechnology Investment Banking for JMP Securities. Prior to rejoining the banking industry, Ms. Fischbein held senior corporate positions at two major biotechnology companies: ImClone Systems and Human Genome Sciences. Ms. Fischbein started her career at Lehman Brothers, JP Morgan Chase and Citigroup, and was a Managing Director for many years at both JP Morgan Chase and Citigroup. Ms. Fischbein has a BA from Harvard University in economics and an MBA from Harvard Business School.
Dr. Band is a co-inventor of the CytoDel technology and a co-founder of CytoDel. Dr. Band has extensive bench-to-bedside experience in biotechnology startups as former Vice President Research of Biomatrix, an NYSE company now owned by Sanofi. Dr Band returned to NYU in 2001, where he began work on botulinum toxin and was appointed to the faculty of the Department of Orthopedic Surgery, Biochemistry and Molecular Pharmacology. Dr Band co-founded and directed the Center for Clinical Research at the NYU-Langone Orthopedic Hospital, and the NYU-Langone Arthritis and Joint Preservation Center. Dr. Band has published more than 80 peer-reviewed research studies in both basic and clinical sciences, and has been issued 15 US patents to date. Dr. Band continues to serve as a Research Professor in the Departments of Orthopedic Surgery, Biochemistry and Molecular Pharmacology, NYU School of Medicine.